30 results about "Phobias" patented technology

An NMDA antagonist (such as ketamine) is administered with a safener (such as clonidine) in patients suffering from neurologic disorders other than pain. The ketamine is adminsitered at a dosage that causes slurred speech, for a span of several days. This treatment enables a patient's nervous system to return to a healthy “set point”, also called an improved stable neural homeostasis, in a manner similar to a broken bone healing itself if protected from jostling and reinjury by a cast. In at least some patients, this treatment can ease problems such as addictions to illegal or pain-killing drugs, nicotine, or alcohol, compulsive or criminal behavioral problems, severe depression, obsessive-compulsive disorders, phobias, etc. It may also provide some relief in some patients for problems such as chronic fatigue, chemical sensitivities, allergies, autoimmune disorders, and diabetes.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

This invention is directed to pharmaceutical compositions and methods for treating a disorder or condition selected from the group consisting of depression, anxiety disorders, phobias, avoidant personality disorder, eating disorders, chemical dependencies, Parkinson's diseases, obsessive-compulsive disorder, negative symptoms of schizophrenia, cognitive dysfunction related to schizophrenia, premenstrual syndrome, stress-induced incontinence, headache, neuropathic pain, chronic pain, urinary incontinence, post-traumatic stress disorder, chronic stress, acute stress, fibromyalgia, depression comorbid with fibromyalgia, obesity, migraine and a combination thereof in a mammal. The methods in one embodiment comprise administering to a mammal in need of treatment for the disorder or condition: (i) at least one serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; (ii) at least one norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the norepinephrine reuptake inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined in the specification; and (iii) a pharmaceutically acceptable carrier. The pharmaceutical compositions and methods of the invention are also useful for preventing a relapse associated with one of the foregoing disorders or conditions, and for treating a symptom associated with one of the foregoing disorders or conditions, wherein the symptom is selected from the group consisting of cognitive dysfunctions and somatic complaints.

The present application describes compounds, including all pharmaceutically acceptable salts, prodrugs, solvates and stereoisomers thereof, according to Formula I, pharmaceutical compositions, comprising at least one compound according to Formula I and optionally at least one additional therapeutic agent and methods of treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using compounds according to Formula I

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof,

• • (ii) a 5-HT_1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT_1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

The present application provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

The present invention relates to the use of anatiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-mentrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resistant" patients.

Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples of a depressive symptom which can be treated or prevented include depressed mood; sadness; anxiety; "empty" feelings; loss of interest or pleasure; irritability; restlessness; changes in appetite or weight; sleep disturbances; lack of or decreased energy; feelings of worthlessness; guilt; helplessness; anger and hostility; difficulty in thinking, concentrating,or making decisions; hopelessness; tiredness; fatigue; memory difficulties; tearfulness; brooding; phobias; excessive worry over physical health; sexual dysfunction; persistent physical symptoms thatdo not respond to treatment; and combinations thereof. These depressive symptoms can be associated with a depressive state or depressive disorder or can be found sub-clinically or not associated withthese depressive states/disorders (e.g., not part of a syndrome or psychiatric disorder).

A new treatment methodology and pharmacological composition for the treatment and remission of Parkinson's Disease and other neurological diseases are provided. The medication and treatment are based on the use of a combination of a phosphodiesterase inhibitor medication, commonly used to treat male erectile dysfunction, and a high-dose of serotonergic synaptic reuptake inhibitor medication, commonly used to treat depression, anxiety disorders, obsessive compulsive disorder and various panic phobias.

The treatment regime is based upon the discovery that the primary cause of PD and various other related neurological conditions is dysfunction in the serotonergic pathways involving the brainstem, nucleus of Raphe, and various projecting serotonergic fibers. It has been determined that this dysfunction can be overcome by increasing the levels of the ligands and neurotransmitters cyclic-GMP and serotonin and the consequential increased binding of these ligands and neurotransmitters to efferent neuron receptors in the synapse. Testing indicates that the inventive treatment changes Parkinson's Disease from a debilitating, progressive, frightening, and previously untreatable pre-morbid condition to one that is rapidly reversible.

The invention relates to a compound of formula (I):wherein:A represents an optionally substituted benzene ring,B represents an imidazoline ring of formula (Ia) or (Ib):and medicinal products containing the same/are useful in treating or in preventing depression, obesity, panic attacks, anxiety, obsessive-compulsive disorders, cognitive disorders, phobias, impulsive disorders associated with the abuse of drugs and withdrawal therefrom, sexual dysfunctions, and Parkinson's disease.

The invention provides an establishment method of an animal model for phobia or phobia-relevant diseases of non-human mammals and application of the animal model and particularly provides a preparation method of the animal model. The preparation method comprises the following steps: (a) providing non-human mammal cells, and inactivating Glce genes in the cells, so as to obtain the non-human mammal cells with the inactivated Glce genes; and (b) preparing the animal model with the inactivated Glce genes for the phobia or the phobia-relevant diseases by virtue of the cells with the inactivated Glce genes prepared in the step (a). The animal model is an effective animal model for the phobia or the phobia-relevant diseases, can be used for researching diseases of the phobia, social phobia, topophobia and the like and further can be applied to the screening and tests of specific drugs.

The invention discloses a psychological intensive phobia patient testing device. The testing device comprises a base, wherein an upper end of the base is fixedly connected with two supporting pipes, upper ends of the two supporting pipes are fixedly connected with the same box body, a collecting plate is fixedly installed in the box body, a transmission mechanism is rotatably arranged on the collecting plate in a penetrating mode, an upper end of the transmission mechanism is fixedly connected with a testing mechanism, a lower end of the transmission mechanism is rotatably connected with a bottom of the box body, a cleaning mechanism for the testing mechanism is rotatably arranged on the collecting plate in a penetrating mode, a worm is rotatably arranged on a side wall of the box body in a penetrating mode, the cleaning mechanism and the transmission mechanism are both in transmission connection with the worm, and a cleaning opening is formed in a side wall of a rear end of the box body above the collecting plate. In a process of testing dense phobia at different degrees, the testing mechanism can be cleaned, definition of the testing mechanism is ensured, accuracy of a test result is improved, in addition, a tested patient can be cooled, tension degree of the patient is reduced, and accurate testing is facilitated.

Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R⁸; R¹ is chosen from: alkyl or haloalkyl; R² is chosen from: H, C(O)R⁶, C(O)OR⁶, SO2R⁶ or C(O)NR⁶R⁷; R³, R⁴ and R⁵ are independently chosen from: H or alkyl; R⁶ and R⁷ are independently chosen from: H or alkyl; and R⁸ is chosen from: OH, CN, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, C(O)R⁶, C(O)OR⁶, SO2R⁶ or C(O)NR⁶R⁷.

System and methods for therapy involving the use of three-dimensional articles of manufacture having printed media at predetermined locations thereon to overcome a therapeutic issue, such as (but not necessarily limited to) fear, phobias, trauma, addiction, grief, depression, feelings of loss, physical pain and diabetic neuropathy. By using the system and methods of the present invention while focusing on emotional and/or physical pain associated with a therapeutic issue, both hemispheres of the brain are activated and random stimulation via place or grid cells and their associated complex circuits occur, which collectively causes or creates new neural connections in the brain of the patient to thereby diminish or even resolve the emotional and/or physical pain associated with the therapeutic issue.

This invention relates to antisense oligonucleotides directed against the mRNA of the corticotropin releasing factor subtype-2 (CRF2) receptor which substantially reduce expression of CRF2 receptors in the rodent brain and the use of antisense oligonucleotides in in vivo CNS studies of gene function and to treat a wide range of psychiatric disorders including anxiety, obsessive-compulsive disorder, panic disorders, post-traumatic stress disorder, phobias and depression.

Provided is a method for preventing or treating an emotional or behavioral problem in a non-human animal, such as fears, phobias, anxieties and aggression, by administering a lactic acid bacterium the non-human animal in need thereof

The disclosure provides systems and methods for reducing anxiety in an occupant of a vehicle. Exemplary embodiments described in the disclosure are generally directed to systems and methods for reducing anxiety in an occupant of a vehicle. In one exemplary method, a computer that is provided in a vehicle receives from a source such as a server computer, information that is used to determine a behavioral profile of an occupant of the vehicle. The computer utilizes the behavioral profile to identify a behavior characteristic of the occupant. The behavior characteristic is matched by the computerto one of various behavior categories such as an amaxophobia sufferer category or a controlling personality category. The computer then executes one or more operations in the vehicle based on the behavior category to which the occupant belongs. If the occupant belongs to the amaxophobia sufferer category, the computer may, for example, play an audio track, display a video clip, and/or change a driving characteristic of the vehicle.

The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitors.

The invention relates to a medicine for treating social anxiety disorder, belongs to the technical fields of medicines and aims at solving the social anxiety disorder problem of some patients suffering from the social anxiety disorder. The social anxiety disorder is analyzed, besides psychological and historical reasons of the patients, physique reasons comprise liver fire and phlegm heat, internal disturbance of evil and wind and obstruction of blood vessels and orifices, and a split vision phobia is treated by combining the following traditional Chinese medicines with the effects of clearing liver fire, purging heat and reducing phlegm, regulating qi and removing stasis as well as tranquilizing mind: 10 parts of rhizoma pinellinae praeparata, 15 parts of curcuma aromatica, 10 parts of rhizoma typhonii, 10 parts of dragon bone, 15 parts of mongolian snake gourd, 9 parts of Chinese rhubarb, 10 parts of cape jasmine, 15 parts of indigo naturalis, 15 parts of raw peach kernel, 10 parts of fructus aurantii, 15 parts of uncaria, 12 parts of compound of glauber-salt and liquorice, 10 parts of bamboo shavings, 9 parts of vermiculite schist seu and 4 parts of angelica root. The medicine for treating the social anxiety disorder can suit the remedy to pathogenesis and has an obvious treatment effect.